Minimally invasive aortic valve replacement has been used for more than 20 years, but its uptake has been limited. The volumes have increased steadily over the last 10 years, but it is still not regarded as a mainstream procedure. The issue, to some extent, is due to the lack of perceived evidence that minimal access incisions confer any benefit other than cosmetic appearance. In this article, the current literature on minimally invasive aortic valve replacement is reviewed, and it is concluded that benefits are demonstrable, particularly in higher risk, comorbid settings.
INTRODUCTION
Minimal access aortic valve replacement (MIAVR) is not new; the procedure was first described by Cosgrove and Sabik [1] in 1996, but surgical uptake has been slow and patchy. The widespread introduction of transcatheter aortic valve intervention (TAVI) occurred at a time when interest in MIAVR increased significantly. Whether this was fortuitous or linked because surgeons felt threatened by TAVI is unclear. The incidence of the approach has increased dramatically across Europe over the last 12 years: in Germany, it is reported to be approximately 25%, but in the UK, current estimates suggest only approximately 12% [2] . Kaneko et al. [3] reported, in an Southern Thoracic Society (STS) database review of redo aortic valve replacement (AVR), that the incidence in the USA was 12.0% for hemisternotomy AVR and was 3.6% for an anterior thoracotomy approach. This may be, at least in part, due to a perceived lack of evidence for a clear benefit to the patients coupled with an acknowledgement that it is associated with an increased surgical complexity. With regard to the anterior right thoracotomy approach, specific criteria must be met with regard to patient anatomy, and the procedure particularly increases cross-clamp and bypass times; 'ministernotomy' approaches are associated with an increase in these times but to a much lesser degree. It would be best to regard these 2 minimal access approaches as completely separate, but because the studies in the literature are so diverse, it is difficult to separate the results. What follows is a review of all minimal access techniques available in the literature; undoubtedly, upper hemisternotomy results predominate.
'THE WORD ON THE STREET'
It is generally accepted that MIAVR is a safe and acceptable surgical technique that is regarded as equivalent in outcome to full sternotomy AVR (FSAVR). To illustrate this point, Furukawa et al.
[4] compared MIAVR with standard AVR. The study population was approximately 1000 patients, and after propensity matching, this dropped to 800 patients. The logistic EuroSCORE of the MIAVR cohort was lower when compared with the FSAVR group (6 vs 10), and so, after propensity matching, both cohorts were reduced to a logistic EuroSCORE of 6.
The results showed no difference in outcomes between both the groups from which it was deduced that MIAVR has an equivalent outcome to FSAVR; the study analysed at a low-risk operation, presented a small cohort of patients and that cohort was in itself a low-risk subset. The weakness of this article is that although it is well written, it was totally underpowered to allow any conclusions to be drawn. MIAVR may be as safe as FSAVR, or it could be worse, or it could be better! The authors appreciated this point and stated in the conclusion: 'the wide confidence intervals reflect the still prevailing statistical uncertainty. . .'.
The literature is full of such studies that by themselves shed little light on any benefits of MIAVR. However, when analysing the studies together using meta-analysis, more insights are gained. There have been many meta-analyses on MIAVR, the largest and the strongest of which was by Phan et al. [5] from 2014 summarizing all the available literatures and evidences. A total of 959 studies were identified between 1998 and 2013, and after screening, 12 786 patients were included (FSAVR 60% and MIAVR 40%). The studies were then weighted for quality according to the GRADE system [6] . No differences in outcome were observed for neurology/stroke, respiratory failure, reoperation for bleeding, permanent pacemaker insertion or deep sternal wound infection. There were, however, significant benefits to MIAVR (Table 1) . Mortality, renal failure and transfusion requirements were significantly better with MIAVR. The speed of recovery was faster with MIAVR [intubation time, intensive care unit (ICU) time and hospital stay]. Finally, significantly less pain was associated with MIAVR-this finding has been previously demonstrated in other studies [5, 7] .
MINIMAL ACCESS AORTIC VALVE REPLACEMENT IN HIGH-RISK SETTINGS
One way to potentially examine whether there are benefits from MIAVR is to analyse high-risk patients. MIAVR has been performed more frequently in low-risk populations perhaps for cosmetic reasons. An example is Merk et al. [8] presenting the Leipzig data reporting on 2051 consecutive patients (23.4% MIAVR and 76.6% FSAVR). Patient demographics (Table 2) show that the MIAVR cohort was at a lower risk with younger age, better ejection fraction, less comorbidity and lower logistic EuroSCORE (6.6% vs 11.2%).
Abdullahi et al. [9] , however, demonstrated that the minimally invasive approach in frail octogenarians led to lower mortality rates, a shorter length of stay and fewer discharges from an institution. The study by Kaneko et al. [10] from Boston focused on AVR in patients older than 80 years in the setting of a revision procedure, with patients having either MIAVR or FSAVR in a non-randomized report. Patient numbers were small reducing the statistical opportunities (51 MIAVR and 54 FSAVR), but a strong trend towards reduced mortality was observed in the MIAVR group (3.9% vs 9.3%).
One of the most unexpected outcomes, however, related to the medium-term survival ( Fig. 1) . At 1 and 5 years after surgery, a significant survival benefit from MIAVR was observed, and the median survival (in an elderly population) increased from 52.0 to 81.2 months. The study by Merk et al. [8] , as mentioned previously, reported similar findings: no significant early benefit of MIAVR was observed in a low-risk cohort but improved survival was observed at 5 and 8 years after surgery. At 5 years, survival was 89.3% versus 81.8%, and at 8 years, survival was 77.7% versus 72.8% for MIAVR versus FSAVR, respectively.
The reason for improved intermediate survival is unclear. Most studies report lower transfusion requirements with MIAVR, and blood transfusion is known to reduce intermediate survival. However, the Leipzig paper was one of the few to report increased transfusion requirements in MIAVR. It should be pointed out that only a few articles have reported increased medium-term survival. In a review of the UK MIAVR practice between 2006 and 2012, Attia et al. [11] failed to show a survival benefit; the positive outcome of this study was a significantly decreased length of hospital stay. (Table 3 ) demonstrated that, despite the MIAVR group having greater comorbidity and a higher risk profile, the outcomes were superior for MIAVR.
MINIMAL ACCESS AORTIC VALVE REPLACEMENT IN OBESE PATIENTS
One obvious group of patients who might do well with MIAVR is the obese. Maintenance of chest wall continuity and reduced risk of sternal disruption could be of major benefit. The surgical approach, however, is more challenging, there are little published data and operation times may be adversely increased.
Santana et al. [12] reported 160 cases of minimal access cardiac surgery in obese subjects. The patients were propensity matched with full sternotomy cases, but the patient demographics was variable across the 2 groups, and not all the cases were AVR: AVR 48.4%, mitral valve replacement or repair 48.4% and double-valve replacement 3.2%. Nonetheless, the results demonstrated dramatic differences between groups. The results (Table 4) showed a benefit from minimal access surgery with reduced renal failure, respiratory support, mortality and blood product usage.
BLOOD PRODUCT TRANSFUSION AND BLOOD LOSS
Many articles have shown MIAVR to be associated with lower blood loss and lesser transfusion requirements. To illustrate this, Brown et al. [13] , reporting a large series from Boston, along with Murtuza et al. [14] demonstrated that MIAVR was associated with significantly lower blood loss. It has been argued that the need for transfusion should be the marker used rather than chest drain losses as the latter is a mixture of a number of elements. In the large meta-analysis by Phan et al. [5] , transfusion requirements were significantly reduced in MIAVR patients when compared with FSAVR patients (36% vs 52.4%, P < 0.001). Finally, despite the reduced need for transfusion, it has been noted in several studies that the rate of reoperation for bleeding was similar in both groups [4, 9] .
PAIN
Both meta-analysis [5, 13] and randomized control trials (RCTs) [15] have shown a reduction in pain scores with MIAVR regardless of the incision used. Reduced pain can be anticipated using the anterior thoracotomy approach; however, using partial sternotomy incisions that minimize the chest wall spreading may also be a factor, whereas the inverted Y incision is less stable than the right 3rd or 4th intercostal space J incision, the balanced spreading of the chest wall may also minimize the disruption and strain applied to the posterior costochondral and costovertebral joints.
RESPIRATORY FUNCTION AND VENTILATION TIMES
In their systematic review, Brown et al. [13] found that 17 of the 26 studies reported ventilation times. Patients who underwent a ministernotomy AVR had a 2-h reduction in ventilation time (95% confidence interval = -2.95 to -1.3 h). Murtuza et al. [14] found a weighted mean reduction in ventilation time of 2.86 h (P < 0.00001) in the ministernotomy group, and the large meta-analysis by Phan et al. [5] reported a significant reduction in ventilation time of more than 4 h with MIAVR. This was associated with a reduction in ICU stay of 0.6 days. Although the majority of the studies confirm these results, the findings of reduced ventilation times and ICU stay are not universal.
INCREASED SURGICAL TIMES ASSOCIATED WITH MINIMAL ACCESS AORTIC VALVE REPLACEMENT
Undoubtedly, using minimal access techniques increases the complexity of the procedure, prolongs cross-clamp and bypass times and, as Denton Cooley said, transfers the pain from the patient to the surgeon! Several recent studies using sutureless valve technology have highlighted this. The 3 reported studies using the EDWARDS INTUITY valve (Edwards Lifesciences, Irvine, CA, USA)-Triton, Foundation and Cadence minimally invasive surgery-have all had significant cohorts of MIAVR patients. Crossclamp and bypass times were increased by approximately 10 min using a hemisternotomy approach and were longer still for anterior thoracotomy incisions. Although the results were statistically significant, it is doubtful whether this had a deleterious effect on patient care or outcome. The Cadence minimally invasive surgery study [15] gave excellent insights into the benefits of combining MIAVR with sutureless technology. The study was small but randomized; patients who received the INTUITY sutureless valve underwent MIAVR and patients who received the sutured device underwent FSAVR. The results demonstrated that combining MIAVR with a sutureless valve reduced cross-clamp times significantly (MIAVR 41 min and FSAVR 54 min; P < 0.0001). In other words, combining sutureless technology with minimal access surgery removes some of the extra pain experienced by the surgeon, which Denton Cooley spoke of, and it is likely to increase the number of patients suitable for keyhole surgery.
CONCLUSIONS
It is impossible to tease out any specific benefits of each type of incision or intercostal space entered apart from to say that the anterior right thoracotomy approach can perhaps be regarded as a super-specialist approach. Overall, the data on MIAVR are generally of poor quality as they rely on under-powered studies. Meta-analysis from multiple authors has shown that MIAVR is at the very least safe, and, in all probability, advantageous over FSAVR. Historically, MIAVR has been targeted at low-risk Reproduced with permission from Santana et al. [12] . FFP: fresh-frozen plasma; IQR: interquartile range; PRBCs: packed red blood cells.
patients, but the real benefits probably occur in high-risk comorbid settings. In low-risk populations, the incision is done for cosmetic reasons, and in higher risk settings, it is to confer outcome benefits which may last until the intermediate term.
Most studies show a reduced transfusion requirements and less pain, and a significant number of reports show shorter ventilation times, ICU stay and hospital stay. Given that the cohorts studied are mostly at low risk, the benefits for higher risk patients may be greater.
The rates of uptake of MIAVR have increased steadily over the last few years. What seems to hold the technique back is surgical apathy coupled with a mistaken belief that there is no surgical benefit. From a patient perspective, however, the landscape is altogether different. MIAVR has been shown to be 'non-inferior' to FSAVR, and so a patient would say to the surgeon: 'if it's just as good doc, why do you want to make a large hole in me, cause me more pain, give me more blood and slow my recovery? ' That is not a question that can be easily ignored.
